Cabazitaxel-induced autophagy via the PI3K/Akt/mTOR pathway contributes to A549 cell death

Cabazitaxel has been used to treat castration-resistant prostate cancer since its approval by the US Food and Drug Administration in 2010. However, whether cabazitaxel may inhibit the proliferation of other tissue-derived cancer cells, and its underlying mechanism, remains unknown. In the present st...

Descripción completa

Detalles Bibliográficos
Autores principales: Huo, Ruichao, Wang, Lili, Liu, Peijuan, Zhao, Yong, Zhang, Caiqin, Bai, Bing, Liu, Xueying, Shi, Changhong, Wei, Sanhua, Zhang, Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042750/
https://www.ncbi.nlm.nih.gov/pubmed/27572899
http://dx.doi.org/10.3892/mmr.2016.5648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042750/
https://www.ncbi.nlm.nih.gov/pubmed/27572899
http://dx.doi.org/10.3892/mmr.2016.5648

Ejemplares similares